vs
Side-by-side financial comparison of Kimco Realty (KIM) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $558.0M, roughly 1.1× Kimco Realty). Royalty Pharma plc runs the higher net margin — 34.4% vs 29.8%, a 4.6% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 4.0%). Over the past eight quarters, Kimco Realty's revenue compounded faster (5.6% CAGR vs 4.6%).
Kimco Realty Corporation, headquartered in Jericho, New York, is a real estate investment trust that invests in shopping centers.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
KIM vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $558.0M | $622.0M |
| Net Profit | $166.3M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 37.2% | 62.4% |
| Net Margin | 29.8% | 34.4% |
| Revenue YoY | 4.0% | 4.8% |
| Net Profit YoY | 23.7% | 2.9% |
| EPS (diluted) | $0.46 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $558.0M | — | ||
| Q4 25 | $542.5M | $622.0M | ||
| Q3 25 | $535.9M | $609.3M | ||
| Q2 25 | $525.2M | $578.7M | ||
| Q1 25 | $536.6M | $568.2M | ||
| Q4 24 | $525.4M | $593.6M | ||
| Q3 24 | $507.6M | $564.7M | ||
| Q2 24 | $500.2M | $537.3M |
| Q1 26 | $166.3M | — | ||
| Q4 25 | $151.2M | $214.2M | ||
| Q3 25 | $137.8M | $288.2M | ||
| Q2 25 | $163.0M | $30.2M | ||
| Q1 25 | $132.8M | $238.3M | ||
| Q4 24 | $166.0M | $208.2M | ||
| Q3 24 | $136.0M | $544.0M | ||
| Q2 24 | $119.7M | $102.0M |
| Q1 26 | 37.2% | — | ||
| Q4 25 | 36.4% | 62.4% | ||
| Q3 25 | 34.9% | 70.1% | ||
| Q2 25 | 39.2% | 36.3% | ||
| Q1 25 | 33.6% | 94.0% | ||
| Q4 24 | 31.7% | 60.9% | ||
| Q3 24 | 33.7% | — | ||
| Q2 24 | 32.1% | 50.2% |
| Q1 26 | 29.8% | — | ||
| Q4 25 | 27.9% | 34.4% | ||
| Q3 25 | 25.7% | 47.3% | ||
| Q2 25 | 31.0% | 5.2% | ||
| Q1 25 | 24.8% | 41.9% | ||
| Q4 24 | 31.6% | 35.1% | ||
| Q3 24 | 26.8% | 96.3% | ||
| Q2 24 | 23.9% | 19.0% |
| Q1 26 | $0.46 | — | ||
| Q4 25 | — | $0.49 | ||
| Q3 25 | — | $0.67 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.55 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $1.21 | ||
| Q2 24 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $618.7M |
| Total DebtLower is stronger | — | $9.0B |
| Stockholders' EquityBook value | $10.4B | $9.7B |
| Total Assets | $19.6B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $211.6M | $618.7M | ||
| Q3 25 | $159.3M | $938.9M | ||
| Q2 25 | $226.6M | $631.9M | ||
| Q1 25 | $131.3M | $1.1B | ||
| Q4 24 | $688.6M | $929.0M | ||
| Q3 24 | $789.0M | $950.1M | ||
| Q2 24 | $126.4M | $1.8B |
| Q1 26 | — | — | ||
| Q4 25 | $7.7B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $8.0B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B |
| Q1 26 | $10.4B | — | ||
| Q4 25 | $10.4B | $9.7B | ||
| Q3 25 | $10.5B | $9.6B | ||
| Q2 25 | $10.5B | $9.5B | ||
| Q1 25 | $10.6B | $9.8B | ||
| Q4 24 | $10.7B | $10.3B | ||
| Q3 24 | $10.5B | $10.3B | ||
| Q2 24 | $10.6B | $9.8B |
| Q1 26 | $19.6B | — | ||
| Q4 25 | $19.7B | $19.6B | ||
| Q3 25 | $19.9B | $19.3B | ||
| Q2 25 | $19.8B | $18.3B | ||
| Q1 25 | $19.7B | $17.6B | ||
| Q4 24 | $20.3B | $18.2B | ||
| Q3 24 | $20.1B | $18.0B | ||
| Q2 24 | $19.5B | $17.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.74× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.75× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $258.4M | $827.1M | ||
| Q3 25 | $332.4M | $702.6M | ||
| Q2 25 | $305.4M | $364.0M | ||
| Q1 25 | $223.8M | $596.1M | ||
| Q4 24 | $239.5M | $742.5M | ||
| Q3 24 | $295.9M | $703.6M | ||
| Q2 24 | $294.1M | $658.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $205.4M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 38.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 3.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.71× | 3.86× | ||
| Q3 25 | 2.41× | 2.44× | ||
| Q2 25 | 1.87× | 12.06× | ||
| Q1 25 | 1.69× | 2.50× | ||
| Q4 24 | 1.44× | 3.57× | ||
| Q3 24 | 2.18× | 1.29× | ||
| Q2 24 | 2.46× | 6.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KIM
| Revenues from rental properties, net | $552.8M | 99% |
| Management and other fee income | $5.2M | 1% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
